Methyl 2,4-dihydroxy-3-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-6-pentylbenzoate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: Methyl 2,4-dihydroxy-3-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-6-pentylbenzoate
• 英文别名: methyl 2,4-dihydroxy-3-(3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl)-6-pentylbenzoate
• 化学式: C₂₃H₃₂O₄
• 分子量: 372.505
• InChiKey: GSBCCWIIKCFQKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  27
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] CANNABIDIOLIC ACID ESTERS FOR TREATING MUSCULAR DYSTROPHY<br/>[FR] ESTERS D'ACIDE CANNABIDIOLIQUE POUR LE TRAITEMENT DE LA DYSTROPHIE MUSCULAIRE
  申请人：EPM GROUP INC

  公开号：WO2021137224A1

  公开（公告）日：2021-07-08

  The present invention provides compositions and methods for treating muscular dystrophy. In particular, the present invention provides pharmaceutical compositions and formulations comprising a cannabidiolic acid (CBDA) ester alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating muscular dystrophy.

  本发明提供了用于治疗肌肉萎缩症的组合物和方法。具体而言，本发明提供了包含大麻二酸（CBDA）酯或与一个或多个额外的大麻素化合物结合的药物组合物和配方，以及适用于治疗肌肉萎缩症的药用载体、赋形剂或稀释剂。
• [EN] CANNABIDIOLIC ACID ESTERS FOR COSMETIC OR EDIBLE COMPOSITIONS<br/>[FR] ESTERS D'ACIDE CANNABIDIOLIQUE POUR COMPOSITIONS COSMÉTIQUES OU COMESTIBLES
  申请人：EPM GROUP INC

  公开号：WO2020136648A1

  公开（公告）日：2020-07-02

  The present invention provides cosmetic or edible compositions comprising a cannabinoid component, wherein the cannabinoid component comprises a cannabidiolic acid (CBDA) ester alone or in combination with one or more cannabinoid compound(s), and a physiologically acceptable carrier, excipient or diluent, and uses thereof for improving appearance, well-being and/or general health.

  本发明提供了包含大麻素成分的化妆品或食品组合物，其中大麻素成分包括仅为大麻二酸甲酯（CBDA）酯或与一个或多个大麻素化合物组合，以及生理上可接受的载体、赋形剂或稀释剂，并将其用于改善外观、健康和/或一般健康的用途。
• CANNABINOID ACID ESTER COMPOSITIONS AND USES THEREOF
  申请人：EPM (IP), INC.

  公开号：US20220151972A1

  公开（公告）日：2022-05-19

  The present disclosure provides pharmaceutical compositions including a cannabinoid acid ester compound alone or in combination with one or more additional cannabinoid compounds. In some embodiments, the cannabinoid acid ester compound is a cannabidiolic acid ester. A variety of therapeutic applications in which the cannabinoid acid ester compounds and pharmaceutical compositions find use are also provided, including combination therapies using cannabinoid acid ester compounds and one or more additional therapeutic agents.
• [EN] CANNABIDIOLIC ACID ESTERS FOR TREATING RESPIRATORY DISTRESS INCLUDING ACUTE RESPIRATORY DISTRESS SYNDROME AND CORONAVIRUS<br/>[FR] ESTERS D'ACIDE CANNABIDIOLIQUE POUR LE TRAITEMENT DE LA DÉTRESSE RESPIRATOIRE, DONT LE SYNDROME DE DÉTRESSE RESPIRATOIRE AIGUË ET LE CORONAVIRUS
  申请人：EPM IP INC

  公开号：WO2021224924A1

  公开（公告）日：2021-11-11

  The present invention provides compositions and methods for treating respiratory distress including coronavirus and acute respiratory distress syndrome. In particular, the present invention provides pharmaceutical compositions and formulations comprising a cannabidiolic acid (CBDA) ester alone or in combination with one or more additional cannabinoid compound(s), and a pharmaceutically acceptable carrier, excipient or diluent, for use in treating respiratory distress including coronavirus and acute respiratory distress syndrome.